Telomir Pharmaceuticals, Inc. filed an 8-K on September 18, 2025, announcing new in vitro data for Telomir-1, which shows it inhibits KDM5 histone demethylases and may offer unique cancer and aging therapy benefits. The findings indicate that Telomir-1 has broader activity than existing treatments, potentially leading to significant advancements in epigenetic therapy.